chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Laceration of finger; Exposure via skin contact; Inadvertent exposure to vaccine; This case was reported by a consumer and described the occurrence of laceration of finger in a male patient who received Rabies NVS (RabAvert) for prophylaxis.   On 10th October 2019, the patient received RabAvert. On 10th October 2019, immediately after receiving RabAvert, the patient experienced laceration of finger, exposure via skin contact and inadvertent exposure to vaccine. On an unknown date, the outcome of the laceration of finger, exposure via skin contact and inadvertent exposure to vaccine were unknown.   It was unknown if the reporter considered the laceration of finger to be related to RabAvert.  Additional details were provided as follows: The age at vaccination was not reported. The patient that was at the time of reporting very anxious about rabies, and hope you could kindly answer my question. The patient asked can the inactivated rabies viruses ever become active and infectious again under some circumstances.The patient accompanied someone else to get rabies vaccine (RabAvert). After the injection, the patient picked up the vaccine vial from the garbage can, and found there was one drop or two of the vaccine left in the vial.The patient had a wound on my hand at that time, so if the vaccine got into my wound, was it able to cause rabies to me, which led to laceration of finger, exposure via skin contact and inadvertent exposure to vaccine. The patient knows the vaccine was inactivated by -propiolactone, and it changes the structure of guanine of RNA, but the patient worried that this process was reversible and the inactivated viruses in the garbage can somehow got reactivated and became infectious again.  The patient called CDC and GlaxoSmithKline customer service, but neither of them could answer question. The doctor said the patient would be fine but am still worried. The patient really hope could the reporter answer the question. The patient struggling so much right at the time of reporting.
Beginning three days after receiving my second Pfizer COVID-19 dose, I developed intractable nausea that lasted for 10 days. That same day, I also developed extreme thirst, which persists today (22 days post-vaccine).
Narrative: COVID infection following COVID vaccine series 03/24, Moderna, dose #1 04/29 Moderna, dose #2 07/09 COVID-19 SCR (ORL) not detected 08/08 pt cc: Chills, diarrhea, fatigue, fever, headache, loss of taste or smell, myalgias, nausea, dyspnea, sore throat exposure: unknown 08/13 COVID swab, result: detected 08/13 SARS-COV-2 LINEAGE result: B.1.617.2 08/13 SARS- COV-2 CLADE result: 21A 09/01 COVID swab, result: detected
The day after immunization (January 4, 2020) pain and redness  developed at injection site (size of quarter), 2 days later (January 5, 2020) injection site redness increased (size  of softball)
Disseminated rash associated with vaccination; a non-specific immunological reaction, some sort of mild bacteremia conditiona nd mild generalized vaccinia. On 08/02/02, diagnosed with cellulitis due to CDC IND Vaccinia vaccination that he received 7/23/02 L arm. On 7/31/02, he developed increased swelling and redness down the arm from the site of vaccination. On Thursday 08/01/02 he noted a non-pruritic rash over the abdomen and increased pain, redness, drainage and streaking down the arm at the vaccination on Friday. He was placed empirically on Augmentin for suspected cellulitis complication due to the vaccinia vaccination. Cellulitis symptoms improved with the Augmentin therapy. Digital photos were taken of the scattered macular-papular rash over the trunk, neck, scalp, and face. Assessment: macular papular rash, etiology unclear; possible disseminated vaccinia; possible allergic reaction to Augmentin. Cellulitis of the left arm with lymphangitic spread, complicating a primary immunization with vaccinia vaccine; doubt progressive vaccinia; clinically and historicaly improved. Possible vaccinia virus exposure of his girlfrie.d Unlikely vaccinia virus exposure to his girlfriend's immunocompromised father.
Edit: about an hour after my vaccine I began itching on my neck and got a scratchy throat. Then felt blisters in my mouth and felt a tingly feeling on my face. I had swelling in my eyes, jaw, lips, nose and tongue. And hives on my neck and chest. I went to my local ER and was given IV PEPCID, benedryl and a steriod. Swelling came down significantly and I was discharged home after about 2 hours with a steroid dose pack, Claritin and Pepcid. I now have a strong migraine.
INFLAMATION AROUND THE INJECTION SITE BEGAN ABOUT 5 DAYS AFTER THE SHOT. IT'S GROWN TO ABOUT 4-5 INCHES. AT FIRST I THOUGHT IT COULD BE A REACTION TO THE ADHESIVE BAND AS MY SKIN IS VERY SENSITIVE DO TO BULLOUS PEMPHIGOID. NOW I'M NOT SO SURE. ASIDE FROM ITCHING IT JUST FEELS A TEENY BIT SORE.
JOINTS PAIN; EXTREME EXHAUSTION; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 15-MAY-2021 for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the subject experienced joints pain, and extreme exhaustion. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from extreme exhaustion, and joints pain. This report was non-serious.
Information has been received from a physician concerning a 15 year old white male pt who in 1993 was vaccinated with a 1st dose of Hep-B. The pt did not receive a 2nd or 3rd dose. The same day of the 1st vaccination, the pt experienced a severe headache, which lasted for 1 day. Additional information has been requested.
Extremely sore arm the day after and irregular menstrual cycle 2 days later.  I've never had an irregular cycle in my life, so this was very alarming, however since then, and even after the second dose, I'm back on track.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 76-year-old male patient received BNT162b2 (BNT162B2), on 09Jan2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 30Jan2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 01Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 76 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), on 11Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Radical prostectomy" (unspecified if ongoing); "Known allergies: penicillin" (unspecified if ongoing). Concomitant medication(s) included: ADVIL [IBUPROFEN], start date: 04Jun2022, stop date: 06Jun2022; CODEINE, start date: 06Jun2022, stop date: 07Jun2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Other medication in 2 weeks includes Advil (start date= 04Jun2022, stop date=06Jun2022), Codeine cough syrup (Start date= 06Jun2022, stop date- 07Jun2022). I had recovered from the original COVID infection. Four days after completing the Paxlovid series, my COVID symptoms returned. Adverse event start date: 13Jun2021, start time: 02:00 PM, Outcome: Recovering, treatment AE: No.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: The reported COVID-19 positive after both the doses of COVID-19 immunization is considered ineffective of BNT162B2, and the Company cannot completely exclude the possible causality between the reported events and BNT162B2 administration.
Patient given Tdap (routine 6/18/2010) and had severe local skin reaction/cellulitis?, then admits in past he also had a reaction approximately 2005 to Td with skin rxn/cellulitis.
12 hours after dose-fever-red burning ears and face. Cranial pressure. Cold extremities. Sore skin Daily skin burning.  Flushing.  Cluster headaches since receiving booster. Sometimes it looks like I walked out of Chernobyl.  Occasionally burning is on back,neck and chest.  Experiencing nerve pain from chest up.
PAIN IN SPINE; BODY SORENESS; JOINT PAIN; FLU; VOMITING; CHILLS; SHAKING; HEADACHE; HEART RACING; This spontaneous report received from a patient concerned a 53 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included high blood pressure, and compazine - napazine codeine allergy, and other pre-existing medical conditions included the patient was non alcoholic and non smoker. the patient did not have any drug abuse or illicit drug usage.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, and batch number: 206A21A expiry: UNKNOWN) dose was not reported, administered on 02-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On 02-MAY-2021, the subject experienced heart racing. On 02-MAY-2021, the subject experienced body soreness. On 02-MAY-2021, the subject experienced joint pain. On 02-MAY-2021, the subject experienced flu. On 02-MAY-2021, the subject experienced vomiting. On 02-MAY-2021, the subject experienced chills. On 02-MAY-2021, the subject experienced shaking. On 02-MAY-2021, the subject experienced headache. On 04-MAY-2021, the subject experienced pain in spine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from heart racing, vomiting, and chills on 04-MAY-2021, and shaking, and had not recovered from body soreness, joint pain, headache, pain in spine, and flu. This report was non-serious.
On day eight after vaccine I awoke to find my left deltoid stiff, red, warm and swollen. These symptoms continued for two days.
Broke out in hives on chest and back, burning and itching. Also had moderate headache and fatigue, took Benadryl and symptoms were reduced.
Patient fully vaccinated (Janssen) but not boosted, admitted to the hospital on 02/02/22 and was found to have COVID-19. Patient expired on 02/07/22.
Teen reported to Mother that she had a headache, and that her right eye  and right side of her lips were swelling at about 11:00am  (Mother thought this was due to nerves because of it being the first day of school), then the next morning teen  reported that  She also had a cold sore in her mouth.  Then on 08/13/2019, the school nurse called Mom reporting that the teen had a swollen left jaw and that she had swollen gums on the left side of her mouth. Was not sure if she had wisdom teeth trying to come in or a gum infection. After work (10pm) on 08/13/2019, teen reported to her Mom that her Right arm had been tingling and painful with a red swollen area over lower right deltoid and that the tingling had been happening since Monday but she forgot to tell her . This is when they went to the E.R. E.R. MD treated teen for a medication allergy and then released her to home. Client reports that she is having no symptoms at this time.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 17-MAY-2016 the patient was vaccinated with an improperly stored dose of M-M-R II single 0.5ml dose (rHA, lot # L007577, expiration date 05-MAR-2017, dose and route unknown). This specified lot number vaccine was exposed to temperature excursion three times. The total cumulative excursion time of the first time was 88 hours with the lowest recorded temperature of 33 Fahrenheit degree. The total cumulative excursion time of the second time was 96 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the third time was 16 hours with the highest recorded temperature of 49 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
This is a spontaneous report from a Pfizer sponsored program Pfizer First Connect. A contactable male consumer of an unspecified age reported for himself that he may received TRUMENBA, via an unspecified route of administration on an unspecified date at single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient is a leukemia patient and may have received meningococcal group b rlp2086 in the past (he doesn't remember). The patient was going to school and a breakout of meningitis had broken out at school. He wanted to know if he can get the vaccine. He was wondering if the vaccine is live or dead. He got conflicting reports from two different doctors. With patient having leukemia, agent stated that it may be an adverse event for the fact that caller may have received meningococcal group b rlp2086 in past. The outcome of event leukemia was unknown.
Swelling of L arm, L axilla, L lateral breast. Development of L supraclavicular lymph node. Tenderness to palpation.
Patient was fully vaccinated and got break through COVID; Patient was fully vaccinated and got break through COVID; This is a spontaneous report from a contactable consumer (patient). An adult male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: not reported), via an unspecified route of administration on an unspecified date as dose 2, single and bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: not reported), via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunization. Medical history and concomitant medications were not reported. Patient was fully vaccinated and got break through COVID (medically significant) on 12Aug2021. The patient underwent lab tests and procedures which included COVID-19 test: positive on 12Aug2021. It was unknown if patient received any treatment for the event. Outcome of the event COVID-19 was resolving.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
This spontaneous report was received from a physician via a company representative refers to a 15 month old female patient was enrolled in the Varicella Zoster Virus Identification Program to identify if VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the Oka/Merck vaccine strain. On 21-APR-2015, the patient was vaccinated with (Oka/Merck) VARVIAX (lot #K002045, expiry date 10-FEB-2016) 0.5 ml in the left arm. On 20-JUL-2015, three months after vaccination, the patient experienced cough, nasal congestion and maximum body temperatures was 102.0 Fahrenheit. The patient also experienced rash which was blistering and burning, diagnosis was made to herpes zoster. The patient was prescribed acyclovir 200 mg/5ml for the treatment and was given counseling. On 20-JUL-2015, the patient had varicella zoster detected by immune-fluorescent monoclonal antibody staining in spin amplified shell vial culture, no herpes simplex virus (HSV) was isolated in the HSV culture. On the same day, aerobic bacterial culture had no growth in 36-48 hours. An examination was performed including the  scalp (including hair inspection) head (including face), lips but not teeth and gums, neck, chest, abdomen, back, right upper extremity, left upper extremity, and inspection and palpation of digits and nails. Findings all the examinations was normal. The reporter stated that the lesions should be treated within 48 hours of onset with anti-virus therapy. The patient's recovered from the events on an unspecified date in 2015. The reporter did not provide the relatedness of the events with (Oka/Merck) VARIVAX. Additional information has been requested.
The day after vaccine, I felt like I had the flu. I didn't have energy and my joint hurts a lot. More than usual. I felt like crap. Usually, my joint pain fluctuates depending on the time of the month. Usually it increase a little the week prior to period and flares a little the week of my period. But now after the vaccines,  the joint pain is more - I'm really comfortable only two days of the month instead of a month a two. There is a lot more pain in my hips.  My hip pain has become much more chronic now after the vaccine. I have been on the chiropractor and get a massage every month, too. I try to keep that in a functional range. It may be helping it from getting worse, but I don't know, it's pretty bad. The pain is ongoing and more persistent in the hips.
Child had slight cold symptoms, broke out with varicella like rash down abdomen two days ago. Confirmed at Dr's visit today.
Covid Vaccination Arm:  Received Moderna vaccine and did experience swelling, rash and hot to the touch at injection site a day later.  Reaction started to go away after a few days.  Then a week later, the rash reappeared,  the swelling increased and  it was hot to the touch.  It never hampered me and I will still get my second dose on 3/14/21.  I will get the 2nd dose on the other arm. As of today, the swelling, heat and an obvious rash is  is still there even though it is 15 days after my first dose. I did receive the first Shingrix dose on 12/30/20 on the same arm as my first dose of Moderna for Covid19.
Arm is still hurting at injection site. Patient was given pain meds by doctor and will be having an MRI.
Very strange rash. It was 3 inches*1.5 inches wide; Infection in right arm just where nurse gave the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Very strange rash. It was 3 inches*1.5 inches wide) and VACCINATION SITE INFECTION (Infection in right arm just where nurse gave the vaccine) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included APIXABAN (ELIQUIS) for an unknown indication.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced VACCINATION SITE RASH (Very strange rash. It was 3 inches*1.5 inches wide) and VACCINATION SITE INFECTION (Infection in right arm just where nurse gave the vaccine). At the time of the report, VACCINATION SITE RASH (Very strange rash. It was 3 inches*1.5 inches wide) and VACCINATION SITE INFECTION (Infection in right arm just where nurse gave the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Ache, redness, swelling and heat at injection site and throughout upper arm beginning shortly after injection. Still significant at 54 hours. Nausea and decreased appetite, 36 hours. Fatigue, 48 hours. Headache, 48 hours. Chills and shivering, 36 hours.
a patient was administered Imovax Rabies vaccine on day 0 on 24-JUL-2019, Day 8 on 01-AUG-2019 and Day 15 on 15-AUG-2019; Initial information received on 15-Aug-2019 regarding an unsolicited valid non-serious case received from a consumer.  This case involves a 75 years old male patient who was administered RABIES (HDC) VACCINE [IMOVAX RABIES] vaccine on day 0 on 24-Jul-2019, day 8 on 01-Aug-2019 and day 15 on 15-Aug-2019 lot number not reported via unknown route in unknown administration site.  The patient's past medical history included Animal bite on 24-Jul-2019. The patient's past medical treatment(s), vaccination(s) and family history were not provided.  It was an actual medication error due to inappropriate schedule of vaccine administered.  Adverse event was not reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  Information on the batch number was requested.  List of documents held by sender: none.
This initial report was received from a registered nurse concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided. On 20-NOV-2016, the patient was vaccinated with an expired dose of PNEUMOVAX 23 lot number L022795 with expiration date 05-NOV-2016 (dose, strength and route of administration were not reported). No adverse effects were reported. This is one of two reports from the same source (MARRS 1611USA011835). Additional information has been requested.
Information has been received on 22-FEB-2019 regarding a case in litigation from a lawyer concerning a female patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 24-DEC-2013, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a physician at a physician's office. On an unknown date, the patient was treated by a healthcare provider at a physician's office for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self, loss of services and economic losses. The outcome of the event was unknown. The causality of the event was considered to be related. Additional information has been requested.
Had initial vaccine on 12/21/2020. Broke out in rash reported in a previous report file. After 2nd injection, at some of the exact locations of healing rash from 1st, new eruptions of red raised pruritic rash occurred. Lower abdomen, top of right ribs and nape of neck.
Patient developed a localized raised red rash on left side of nasal bridge/cheek right after receiving vaccine.  Rash did not progress and resolved within 20 minutes.  No redness or swelling at injection sites.  No swelling or respiratory symptoms.
This is a spontaneous report from a contactable consumer. A female patient of unspecified age received bnt162b2 (COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: Unknown), via unspecified route of administration on an unknown date as unknown, single for COVID-19 immunisation. On an unknown date, the patient experienced headache, fever, chill, muscle pain and low energy. The outcome of all the events was unknown. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This report describes an increased ferritin level in a 55 y.o. male who received Hap A vax inactivated. The PT had no relevant medical history and had no concomitant medications. He received his first injection of Hep A vax w/no problems noted. On 3/12/02, the vaccinee received his 2nd dose of Hep A vax inactivated. On 3/26/02, his ferritin level was found to be increased. The reporter stated that the increased ferritin level was possibly due to Havrix. As of 5/7/02, the event was ongoing.